Close Menu

Adaptive Biotechnologies

The sequencing-based test for minimal residual disease can be use with blood and bone marrow samples in patients with chronic lymphocytic leukemia.

Assessing T cell fraction alongside tumor thickness was superior to other histopathological variables for accurate progression-free survival prediction.

Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.